ArticleCardiovascular diabetology2026
Chronic kidney disease onset, progression, and cardiovascular outcomes: proteomics informs biology and risk stratification.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundLarge-scale proteomics provides an opportunity to understand chronic kidney disease (CKD) and cardiovascular disease, yet research in this field is limited. This study utilized proteomics to inform biology and risk stratification for these diseases.
methodsThis cohort study included 44,779 participants free of prevalent CKD, and 3,749-4,272 participants with prevalent CKD from the UK Biobank. The Olink Explore 3072 platform quantified 2,923 plasma proteins. Cox proportional hazards models were used to assess associations of proteins with kidney diseases including CKD and end stage kidney disease, and cardiovascular diseases including coronary heart disease (CHD), stroke, and heart failure (HF). Mendelian randomization examined genetic associations, pathway analyses identified biological pathways, and predictive models were developed for incident diseases.
resultsMedian follow-up periods were 12.2-12.6 years. We identified 598 (20.5%) proteins shared across ≥ 2 diseases, with 595 (20.4%) showing consistent directions of associations, and 471 (16.1%) unique to a single disease. CKD and HF specifically shared the largest number of 279 (9.6%) proteins. POLR2F, TNFRSF10B, and IGFBP2 were positively associated with all five diseases, with Mendelian randomization supporting genetic associations of POLR2F with CHD and IGFBP2 with hypertensive renal disease. Pathway analyses highlighted cell adhesion, signal transduction, and cytokine-cytokine receptor interaction for disease-associated proteins. Incorporating predictive proteins into clinical models improved risk prediction for CKD, CHD, stroke, and HF, yielding Harrell's C indices of 0.750-0.818 (corresponding increases of 0.027-0.090).
conclusionsThis study deepens insights into disease biology and provides a foundation for early detection and integrated risk stratification in CKD and cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.